Skip to content
OpenCapital
Get started

ImmunityBio, Inc. IBRX Accrued research and development costs

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%—
Debt / equity0.1×—
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept ibrx:AccruedResearchAndDevelopmentCosts.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s accrued research and development costs.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s accrued research and development costs?
ImmunityBio, Inc. (IBRX) reported accrued research and development costs of $3.04M in Q1 2026.
How has ImmunityBio, Inc.'s accrued research and development costs changed year-over-year?
ImmunityBio, Inc.'s accrued research and development costs increased by 33.8% year-over-year, from $2.27M to $3.04M.
What is the long-term trend for ImmunityBio, Inc.'s accrued research and development costs?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s accrued research and development costs has grown at a -8.0% compound annual growth rate (CAGR), from $4M to $2.64M.